Preparing a medical device registration in Peru requires more than translating a technical file. Correct classification in Peru is the foundation of the entire DIGEMID submission, and getting it right the first time saves manufacturers weeks, sometimes months, of avoidable back-and-forth with the regulator.
This article explains the three pillars that determine a solid classification in Peru: the GMDN nomenclature, the Instructions for Use (IFU), and the manufacturing process documentation. Understanding how these elements interact helps you build a submission that DIGEMID can review efficiently, one that reflects the same regulatory logic already used in your FDA, CE/MDR, Health Canada, or TGA files.
Why classification in Peru deserves early attention?
In Peru, medical devices and biomedical equipment are registered with DIGEMID, the national health regulatory authority. As in most jurisdictions, the risk class assigned to a device determines the depth of the technical dossier, the type of evidence required, and the overall review timeline.
A device that is misclassified, or supported by inconsistent documentation, is one of the most common causes of observations and delays during evaluation. Most of these issues can be prevented by aligning three elements before submission: the nomenclature used to identify the device, the intended use described in the IFU, and the manufacturing information provided to the authority. Addressing these points upstream, rather than reacting to DIGEMID queries, is the most efficient path toward a smooth registration in Peru.
The role of GMDN in Peru
The Global Medical Device Nomenclature (GMDN) is an internationally recognized system used to identify and classify medical devices in a standardized way. Each device type is assigned a unique five-digit GMDN code, a generic name, and a precise definition.
As part of the DIGEMID registration process, applicants are generally required to provide the common name of the device, its nomenclature code, and the international nomenclature standard used, such as GMDN or UMDNS. This requirement is a direct input into classification in Peru, since it allows the regulator to identify precisely what the device is before assessing its risk category.
GMDN also facilitates traceability and post-market surveillance, harmonizes communication between manufacturers, distributors, and regulators, and because it is already used in most major markets, acts as a bridge between your Peruvian submission and documentation prepared for other regions.
Is GMDN mandatory?
Applicants must provide a universal nomenclature name with its identification code, and GMDN is specifically recognized as one accepted standard. Peruvian regulations also allow other systems, such as UMDNS, so GMDN is not the only option, but it remains the most widely used and the most easily transferable across jurisdictions, making it the preferred choice for manufacturers managing multiple Latin American submissions.
Why the IFU matters for classification in Peru?
The IFU is often treated as a downstream document, finalized once classification and clinical evidence are settled. For a Peruvian submission, this order should be reconsidered: the IFU is one of the primary sources DIGEMID uses to confirm the intended use and therefore the risk class of a device.
The intended use statement must be fully consistent with the GMDN term and description selected for the device. Any discrepancy between what the IFU claims and how the device has been classified is likely to raise a reviewer question, extending the evaluation timeline.
Beyond the intended use statement, the IFU should reflect the same risk-relevant details already validated in other markets: contraindications, warnings, handling instructions, and storage conditions. Reusing IFU content prepared for FDA, CE/MDR, Health Canada, or TGA submissions is generally acceptable, provided it is accurately translated into Spanish and adapted to local terminology. Manufacturers who verify IFU consistency before submission typically experience a more predictable review, since DIGEMID can cross-check nomenclature, classification and intended use without ambiguity.
The role of manufacturing process documentation
The third pillar of a strong submission is the manufacturing process description. While less directly linked to classification in Peru than nomenclature or intended use, this information supports the credibility of the entire technical file.
DIGEMID expects evidence that the device is produced under a recognized quality management system, most commonly ISO 13485, along with a clear description of the manufacturing site and key production stages. This confirms that the risk controls tied to the assigned classification are actually implemented, not only described on paper.
To support classification in Peru efficiently, manufacturers should prepare: a summary of the manufacturing process, evidence of the quality management system in place (e.g., an ISO 13485 certificate), identification of manufacturing sites and any subcontractors involved in critical steps and relevant certificates already obtained for other markets, which DIGEMID may accept as supporting evidence. Since much of this documentation already exists for FDA, CE/MDR, Health Canada, or TGA files, the additional effort for Peru is usually limited to compiling and translating existing evidence.
Practical recommendations
Before starting the dossier, gather directly from the manufacturer: the GMDN code assigned to the device, the official GMDN term or generic name and the corresponding GMDN description. This information is often already available in FDA, CE/MDR, Health Canada, or TGA technical files and can be reused rather than recreated. For example, GMDN 47569 corresponds to a single-use scalpel, a generic name and definition that can be transferred directly into a Peruvian dossier.
For manufacturers expanding across Latin America, GMDN is increasingly valuable, as it is recognized by many regulatory authorities worldwide and facilitates harmonization of technical documentation across jurisdictions. Combining accurate GMDN data with a consistent IFU and a complete manufacturing file gives manufacturers a strong foundation for classification in Peru and a smoother path through the DIGEMID review process.
PARTNER WITH MANDALA INTERNATIONAL
Optimizing classification in Peru before submission is a matter of preparation, consistency and access to the right regulatory expertise.
Mandala International supports medical device manufacturers throughout Latin America, from nomenclature selection to full dossier preparation, ensuring every submission reflects both local requirements and international best practices.
If you are planning a registration in Peru or elsewhere in Latin America, our regulatory team is ready to help you build a compliant and efficient submission.
By submitting this form, you agree to be contacted by Mandala International and to receive related communications.
About Mandala International
Mandala International is a regulatory and market access partner specialized in Latin America, supporting manufacturers of regulated health products throughout the product registration and commercialization process.
With expertise across Brazi, Mexico, Colombia, Peru and Chile, Mandala International helps companies navigate regulatory frameworks, obtain product approvals, and successfully access Latin American healthcare markets.
Frequently Asked Questions about classification in Peru
Both GMDN and UMDNS are internationally recognized nomenclature systems, and DIGEMID accepts either one to identify a device. GMDN tends to be the preferred choice for manufacturers with a global footprint, since it is already widely used in the technical files prepared for FDA, CE/MDR, Health Canada, or TGA submissions. Using the same nomenclature across markets makes it easier to keep classification in Peru consistent with your other regulatory dossiers.
Yes, in most cases the same core documentation can be adapted for a Peruvian submission. The GMDN code, the IFU, and the manufacturing process evidence prepared for other markets can generally be reused, provided they are translated into Spanish and reviewed for consistency with DIGEMID requirements. This approach significantly reduces the preparation time compared with building a dossier from scratch.
A misclassification typically results in an observation from DIGEMID, requiring the manufacturer to correct the nomenclature, the IFU, or the supporting evidence before the review can proceed. This exchange adds weeks or months to the timeline, which is why verifying the alignment between GMDN, IFU, and manufacturing documentation before submission is so valuable.
No. DIGEMID no longer accepts the Free Sale Certificate (FSC) issued by the China Chamber of Commerce (CCPIT) as valid supporting evidence for medical device registration. Manufacturers sourcing devices from China should verify which alternative certificate or authority DIGEMID currently recognizes before submission, to avoid delays caused by an invalid document. Our regulatory team can help confirm the appropriate documentation for your specific case.
